SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Blomqvist Michael)
 

Sökning: WFRF:(Blomqvist Michael) > (2020-2023) > Leukocyte nadir as ...

  • Poikonen-Saksela, PaulaHelsinki Univ Hosp, Comprehens Canc Ctr, Helsinki, Finland.;Univ Helsinki, Helsinki, Finland. (författare)

Leukocyte nadir as a predictive factor for efficacy of adjuvant chemotherapy in breast cancer. Results from the prospective trial SBG 2000-1

  • Artikel/kapitelEngelska2020

Förlag, utgivningsår, omfång ...

  • Informa UK Limited,2020
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-423818
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-423818URI
  • https://doi.org/10.1080/0284186X.2020.1757149DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:143717713URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Background: Retrospective studies have suggested that chemotherapy-induced leukopenia is associated with improved recurrence-free or overall survival. The SBG 2000-1 trial was designed to verify the favorable prognosis associated with chemotherapy-induced leukopenia in early breast cancer. Patients not experiencing chemotherapy-induced leukopenia were randomized into standard dosed or individually escalated chemotherapy doses based on the grade of leukopenia after a first standard dose.Patients and methods: 1452 women in Sweden and Denmark with operable node-positive or high-risk node-negative breast cancer aged 18-60 years were recruited to participate in this trial. Participants received a first FEC cycle at standard doses (600/60/600 mg/m(2)). Patients (n = 1052) with nadir leukopenia grade 0-2 after the first cycle were randomized between either 6 standard FEC or 6 tailored FEC courses with doses of epirubicin and cyclophosphamide escalated during courses 2 and 3 and thereafter aimed at achieving grade 3 leukopenia. Patients with nadir leukopenia grade 3-4 after the first course continued treatment with standard FEC. Results of the randomized comparison has been published previously. The present study focuses on chemotherapy-induced leukopenia as a covariable with outcome in randomized and non-randomized patients. The prognostic value of leukopenia after course 3, was studied in a Cox model adjusted for cumulative doses of epirubicin and cyclophosphamide. The association of chemotherapy-induced leukopenia with prognosis was a preplanned secondary endpoint for this trial.Results: The eight-year distant disease-free survival was 73%, 77%, 78% and 83% for patients with leucocyte nadir grade 0, 1, 2 and 3-4, respectively. Higher degree of leukopenia was highly significantly associated to improved distant disease-free survival (HR 0.84, 95% CI 0.74-0.96, p = .008) and overall survival (HR 0.87 (0.76-0.99, p = .032).Conclusion: This prospective study confirms that chemotherapy-induced leukopenia is a covariable with outcome in primary breast cancer, even after adjustment for chemotherapy doses.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Lindman, HenrikUppsala universitet,Experimentell och klinisk onkologi(Swepub:uu)henrlind (författare)
  • Sverrisdottir, AsgerdurSodersjukhuset, Dept Oncol, Stocholm, Sweden.;Landspitali Univ Hosp, Dept Oncol, Reykjavik, Iceland. (författare)
  • Edlund, PerGävle Cent Hosp, Dept Oncol, Gävle, Sweden. (författare)
  • Villman, KennethÖrebro Univ Hosp, Dept Oncol, Örebro, Sweden. (författare)
  • Nittby, Lena TennvallSkane Univ Hosp, Dept Oncol, Malmö, Sweden. (författare)
  • Cold, SorenOdense Univ Hosp, Dept Oncol, Odense, Denmark. (författare)
  • Bechmann, TroelsHosp South West Jutland, Dept Oncol, Esbjerg, Denmark.;Vejle Hosp, Dept Oncol, Vejle, Denmark. (författare)
  • Stenbygaard, LarsAalborg Univ Hosp, Dept Oncol, Aalborg, Denmark. (författare)
  • Ejlertsen, BentRigshosp, Dept Oncol, Copenhagen, Denmark. (författare)
  • Andersson, MichaelRigshosp, Dept Oncol, Copenhagen, Denmark. (författare)
  • Blomqvist, CarlHelsinki Univ Hosp, Comprehens Canc Ctr, Helsinki, Finland.;Univ Helsinki, Helsinki, Finland.;Örebro Univ Hosp, Dept Oncol, Örebro, Sweden. (författare)
  • Bergh, JonasKarolinska Institutet (författare)
  • Ahlgren, JohanGävle Cent Hosp, Dept Oncol, Gävle, Sweden.(Swepub:uu)joahl839 (författare)
  • Helsinki Univ Hosp, Comprehens Canc Ctr, Helsinki, Finland.;Univ Helsinki, Helsinki, Finland.Experimentell och klinisk onkologi (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Acta Oncologica: Informa UK Limited59:7, s. 825-8320284-186X1651-226X

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy